Bio-Path enters LOI for asset acquisition of DNA programs
Bio-Path Holdings enters a non-binding Letter of Intent with Farrington Capital to potentially acquire or out-license key DNA programs and the DNAbilize platform. This potential asset sale follows the buyer securing a loan facility and offers Bio-Path a path to monetize its biolo
View filing at SEC.gov →